LONDON (Alliance News) - Amryt Pharma PLC on Thursday said it has expanded its Lojuxta licence agreement with Aegerion Pharmaceuticals Inc into Russia, the Commonwealth of Independent States, and non-EU Balkan countries.
The original agreement with Aegerion covered the EU, the Middle East & North Africa, Switzerland, Turkey, and Israel.
Lojuxta is a treatment used for adults with the cholesterol disorder homozygous familial hypercholesterolaemia.
Amryt shares were down 1.0% on Thursday at 17.53 pence each.
